Findings: RCTSTEP-HFpEF DM trial - Semaglutide vs Placebo in Obese Diabetics with HFpEF, NEJM (2024) [PubMed abstract] Design: Randomized, placebo-controlled trial (N=616 | length = 52 weeks) in obese type 2 diabetics (BMI 30) with HFpEF Treatment: Semaglutide titrated to 2.4 mg once weekly vs Placebo Primary outcome: Change from baseline in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS
TAP Micro devices have been successfully employed by hospitals and medical professionals for investigational use to conduct remote blood collection on a wide range of patients spanning ages and conditions, validating its flexibility and effectiveness in the field
Median home price $427,000, 4% above national median
To date several clinical trials have been conducted to test IGF-1 under several conditions and an infinity of animal models have been used to investigate its deficiency, treatment and to exploit its actions
Even though tirzepatide was associated with better survival, the use of incretin analogues to treat non-obese heart failure patients needs careful consideration due to this drastic weight loss
January savings to support your goals All January long at Pharmacy Innovations , enjoy: 15% off weight-management supplements , including L-Carnitine, multivitamins, Vitamin B12, magnesium glycinate, fiber supplements, omega-3s, probiotics, Berberine, HiPhenolic, Glunozym and digestive enzymes
